The iPSCs Manufacturing Services Market Size is valued at 1095.8 Million in 2022 and is predicted to reach 2994.6 Million by the year 2031 at a 12.19 % CAGR during the forecast period for 2023-2031.
Induced Pluripotent Stem Cells (iPSC) are originated from skin or blood cells. iPSCs are cells that are reprogrammed from somatic cells using different transcription factors. These cells are pluripotent, have the potential for self-renewal, and can differentiate into any of the 220+ human cell types. iPSC has certain advantages over other stem cell types in regenerative medicine and wound healing models. iPSCs are used to produce patient-specific cells, which can be transplanted to the site of injury or tissue degeneration due to various disease conditions. iPS cells have the potential to become embryos if exposed to suitable conditions. Some important characteristics of iPSC are abundant somatic cells of the donor that can be used. Issues of histocompatibility with donor/recipient transplants can be avoided. Very useful for drug development and developmental studies.
Market growth factors are increasing research on personalized or precise medicine and extended applications in regenerative treatments and therapies due to the high therapeutic potential of iPS cells. Uprising trials and research on diseases like Parkinson's disease, Anemia, and cardiac syndromes will contribute to iPSC production. In the manufacturing of iPS cells, the use of an automated platform will boost the market with cost reduction and increased output. In Apr 2022, Ncardia launched a new business, Cellistic™, to focus Ncardia's induced pluripotent stem cell (iPSC) expertise on cell therapy development and manufacturing. Affordable cost for cell therapy and demonstration of these therapies' safety and efficacy are market restraining factors. Also, methods for ensuring reproducibility and maintenance, as differentiated tissues are uncertain, are expected to hamper the market growth. The standard technique to create iPS cells uses viruses to transfer the reprogramming genes into the skin cells, which is one of iPS cells' cons.
Tumorigenicity, immune rejection, phenotypic heterogeneity of therapeutic cell products and genetic instability are prime challenges in stem cell research that will impact the production of iPS Cells.
Competitive Landscape
Some Of The Key Players In The IPSCs Manufacturing Services Market:
- I Peace Inc.,
- Lonza Group AG,
- Axol Bioscience Ltd.,
- FUJIFILM Cellular Dynamics, Inc.,
- Pluristyx, Inc.,
- Ncardia,
- Cynata Therapeutics Limited,
- Evotec SE,
- Celogics Inc,
- Catalent, Inc,
- CCRM,
- Applied StemCell Inc. (ASC),
- RoslinCT,
- Takara Bio Inc,
- Thermo Fisher Scientific, Inc,
- Other Prominent Players
Market Segmentation
iPSCs manufacturing services market is segmented into two main fragments. The first segmentation is by application, including Research Products, Drug Development & Discovery, Cellular Therapy, Toxicology Screening, Personalized Medicine, Disease Modelling, Stem Cell Banking, and Emerging Applications. The last segmentation is by end-user, which comprises Pharmaceutical & Biotechnology Companies, Academic institutes, Research Laboratories & CROs, Hospitals & Surgical Centres, Cell & Tissue Banks, Other End Users. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, & the Middle East and Africa.
North America is likely to witness rapid growth in the forecast period, followed by Europe due to fast research on cardiac diseases, neuropathies and personalized medicine production. Also, significant funding for development in iPSC manufacturing will be responsible for the growth.
Recent Development
- In Nov 2023, I Peace, Inc. and Heartseed Inc. collaborated to make cardiomyocytes using Heartseed's unique methods for differentiating and purifying cardiomyocytes from various donor-derived GMP-grade iPS cell lines. Heartseed has regularly been able to make high-purity cardiomyocytes from all of the iPS cell lines that I Peace made for this study.
- In Apr 2023, The Francis Crick Institute made a deal that gave Axol Bioscience the sole right to use a method for creating human pluripotent stem cells (hPSCs) that were used to test drugs and see how harmful they are to the heart. The Crick group created a method that was used to make groups of hPSC-derived left ventricular cardiomyocytes (LVCMs) that were structurally, functionally, and metabolically more mature.
The iPSCs Manufacturing Services Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1095.8 Million |
|
Revenue Forecast In 2031 |
USD 2994.6 Million |
|
Growth Rate CAGR |
CAGR of 12.19 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
I Peace Inc., Lonza Group AG, Axol Bioscience Ltd., FUJIFILM Cellular Dynamics, Inc., Pluristyx, Inc., Ncardia, Cynata Therapeutics Limited, Evotec SE, Celogics Inc, Catalent, Inc, CCRM, Applied StemCell Inc. (ASC), RoslinCT, Takara Bio Inc, Thermo Fisher Scientific, Inc, Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
